Accessibility Menu
Tempest Therapeutics logo

Tempest Therapeutics

(NASDAQ) TPST

Current Price$1.07
Market Cap$17.42M
Since IPO (2021)-99%
5 Year-99%
1 Year-85%
1 Month-17%

Tempest Therapeutics Financials at a Glance

Market Cap

$17.42M

Revenue (TTM)

$0.00

Net Income (TTM)

-$43.10M

EPS (TTM)

-$6.21

P/E Ratio

-0.18

Dividend

$0.00

Beta (Volatility)

1.65 (High)

Price

$1.07

Volume

81,786.63

Open

$1.11

Previous Close

$1.09

Daily Range

$1.05 - $1.12

52-Week Range

$1.02 - $12.23

Estimated Earnings Date

Aug 10, 2026

TPST News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Tempest Therapeutics

Industry

Biotechnology

Employees

4

CEO

Matthew Angel, Ph.D

Headquarters

Brisbane, CA 94080, US

TPST Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-729.89%

Return on Capital

-179.45%

Return on Assets

-400.99%

Earnings Yield

-5.56%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$17.42M

Shares Outstanding

15.98M

Volume

81.79K

Avg. Volume

194.71K

Financials (TTM)

Gross Profit

-$22.25M

Operating Income

-$43.36M

EBITDA

-$42.79M

Operating Cash Flow

-$26.38M

Capital Expenditure

$0.00

Free Cash Flow

-$26.38M

Cash & ST Invst.

$1.81M

Total Debt

$7.85M

Tempest Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$22.18M

N/A

Gross Margin

0.00%

N/A

Market Cap

$17.42M

N/A

Market Cap/Employee

$725.73K

N/A

Employees

24

N/A

Net Income

-$27.70M

-155.0%

EBITDA

-$27.64M

-160.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$1.81M

-91.6%

Total Debt

$7.85M

-40.1%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$6.62M

-15.8%

Short Term Debt

$1.24M

-76.4%

Return on Assets

-4.01%

N/A

Return on Invested Capital

-5.83%

N/A

Free Cash Flow

-$7.60M

+5.5%

Operating Cash Flow

-$7.60M

+5.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BRNSBarinthus Biotherapeutics plc
$0.62-3.26%
ALGSAligos Therapeutics, Inc.
$5.59+2.57%
FGENFibroGen, Inc.
$9.07-1.63%
INMBINmune Bio, Inc.
$1.70+1.19%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$17.92-0.01%
TAT&T
$20.58+0.00%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$12.30-0.15%
CLROClearOne
$6.48+1.01%

Questions About TPST

What is the current price of Tempest Therapeutics?

Tempest Therapeutics is trading at $1.09 per share.

What is the 52-week range for Tempest Therapeutics?

Over the past 52 weeks, Tempest Therapeutics has traded between $1.02 and $12.23.

How much debt does Tempest Therapeutics have?

As of the most recent reporting period, Tempest Therapeutics reported total debt of $7.85M.

How much cash does Tempest Therapeutics have on hand?

Tempest Therapeutics reported $1.81M in cash and cash equivalents in its most recent financial results.

What is Tempest Therapeutics’s dividend yield?

Tempest Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.